TY - JOUR
T1 - Resting Cardiac Efficiency Affects Survival Following Transcatheter Aortic Valve Replacement
AU - Agasthi, Pradyumna
AU - Pujari, Sai Harika
AU - Mookadam, Farouk
AU - Venepally, Nithin R.
AU - Ashraf, Hasan
AU - Fortuin, Floyd David
AU - Wang, Panwen
AU - Allam, Mohamed
AU - Sweeney, John
AU - Eleid, Mackram
AU - Pollak, Peter
AU - Greason, Kevin L.
AU - Beohar, Nirat
AU - Arsanjani, Reza
N1 - Funding Information:
Informed, written consent was obtained from all individuals for whom information is included in this article. The authors have conformed to institutional guidelines and those of the American Physiological Society.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Objective: Cardiac power to left ventricular mass (LVM) ratio, also termed cardiac efficiency (CE), reflects the rate of cardiac work delivered to the potential energy stored in LVM. We sought to assess the association between baseline resting CE and survival post transcatheter aortic valve replacement (TAVR). Methods: We retrospectively extracted data of patients who received TAVR in the Mayo Clinic Foundation with follow up data available at 1 year. Cardiac output was measured using Doppler echocardiography at baseline. CE was calculated using the formula, (cardiac output × mean arterial blood pressure)/(451 × LVM × 100) W/100 g. Survival score analysis was performed to identify cut off value for CE to identify the maximum difference in mortality in the study cohort. Patients were subsequently divided into 2 groups CE < 0.38 W/100 g and CE ≥ 0.38 W/100 g. Survival was determined using Kaplan-Meier method. Results: We included 954 patients in the final analysis. CE in group1 vs group 2 was 0.31 ± 0.05 W/100 g vs 0.59 ± 0.18 W/100 g. Patients in group1 were more likely to be male, had a higher prevalence of atrial fibrillation, prior myocardial infarction, mitral and tricuspid regurgitation. They also had a higher STS risk score, NYHA functional class, and lower aortic valve area. The remainder of the baseline characteristics was similar in both groups. A lower CE was associated with higher 1-year mortality following TAVR based on multivariate analysis. (Group1: 22.18% vs Group 2: 9.89%, p < .0001). Conclusion: In our cohort, a low baseline CE (<0.38 W/100 g) conferred higher mortality risk following TAVR.
AB - Objective: Cardiac power to left ventricular mass (LVM) ratio, also termed cardiac efficiency (CE), reflects the rate of cardiac work delivered to the potential energy stored in LVM. We sought to assess the association between baseline resting CE and survival post transcatheter aortic valve replacement (TAVR). Methods: We retrospectively extracted data of patients who received TAVR in the Mayo Clinic Foundation with follow up data available at 1 year. Cardiac output was measured using Doppler echocardiography at baseline. CE was calculated using the formula, (cardiac output × mean arterial blood pressure)/(451 × LVM × 100) W/100 g. Survival score analysis was performed to identify cut off value for CE to identify the maximum difference in mortality in the study cohort. Patients were subsequently divided into 2 groups CE < 0.38 W/100 g and CE ≥ 0.38 W/100 g. Survival was determined using Kaplan-Meier method. Results: We included 954 patients in the final analysis. CE in group1 vs group 2 was 0.31 ± 0.05 W/100 g vs 0.59 ± 0.18 W/100 g. Patients in group1 were more likely to be male, had a higher prevalence of atrial fibrillation, prior myocardial infarction, mitral and tricuspid regurgitation. They also had a higher STS risk score, NYHA functional class, and lower aortic valve area. The remainder of the baseline characteristics was similar in both groups. A lower CE was associated with higher 1-year mortality following TAVR based on multivariate analysis. (Group1: 22.18% vs Group 2: 9.89%, p < .0001). Conclusion: In our cohort, a low baseline CE (<0.38 W/100 g) conferred higher mortality risk following TAVR.
KW - Aortic valve replacement
KW - Cardiac efficiency
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=85083311093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083311093&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2020.04.015
DO - 10.1016/j.carrev.2020.04.015
M3 - Article
C2 - 32317228
AN - SCOPUS:85083311093
SN - 1553-8389
VL - 21
SP - 1327
EP - 1333
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
IS - 11
ER -